| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000201231 |
| P698 | PubMed publication ID | 7750665 |
| P2093 | author name string | Arnold R | |
| Richter G | |||
| Herrmann C | |||
| Göke B | |||
| Göke R | |||
| Fehmann HC | |||
| P433 | issue | 2 | |
| P921 | main subject | glucose | Q37525 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 117-126 | |
| P577 | publication date | 1995-01-01 | |
| P1433 | published in | Digestion | Q15766219 |
| P1476 | title | Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients | |
| P478 | volume | 56 |
| Q36477333 | Activation of enteroendocrine membrane progesterone receptors promotes incretin secretion and improves glucose tolerance in mice |
| Q36567296 | An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes |
| Q92169716 | An introductory review of resistant starch type 2 from high-amylose cereal grains and its effect on glucose and insulin homeostasis |
| Q64935296 | Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus. |
| Q37225021 | Anorexia of aging and gut hormones. |
| Q51043340 | Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. |
| Q80532417 | Appetite hormones and energy intake in obese men after consumption of fructose, glucose and whey protein beverages |
| Q35825708 | Appetite regulation and weight control: the role of gut hormones |
| Q47328876 | Aversion learning can reduce meal size without taste avoidance in rats. |
| Q35677192 | Bariatric surgery for extreme adolescent obesity: indications, outcomes, and physiologic effects on the gut-brain axis |
| Q37508420 | Bowels control brain: gut hormones and obesity |
| Q37768338 | Bowels control brain: gut hormones and obesity |
| Q73740366 | Calcitonin gene-related peptide potently stimulates glucagon-like peptide-1 release in the isolated perfused rat ileum |
| Q26749211 | Carbohydrate-induced secretion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 |
| Q37204432 | Central and peripheral regulation of food intake and physical activity: pathways and genes |
| Q44621765 | Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects |
| Q34824270 | Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery |
| Q93102690 | Chilled Potatoes Decrease Postprandial Glucose, Insulin, and Glucose-dependent Insulinotropic Peptide Compared to Boiled Potatoes in Females with Elevated Fasting Glucose and Insulin |
| Q36423113 | Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP. |
| Q46718654 | Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells. |
| Q38072272 | Coming full circle in diabetes mellitus: from complications to initiation. |
| Q89551381 | Comparable Postprandial Amino Acid and Gastrointestinal Hormone Responses to Beef Steak Cooked Using Different Methods: A Randomised Crossover Trial |
| Q57491538 | Comparison of Glucose and Satiety Hormone Response to Oral Glucose vs. Two Mixed-Nutrient Meals in Rats |
| Q37092070 | Contributions of fat and protein to the incretin effect of a mixed meal. |
| Q38286591 | Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? |
| Q37939367 | Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. |
| Q40104293 | Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line |
| Q46493618 | Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects |
| Q31665544 | Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. |
| Q40661144 | Development of genetically engineered human intestinal cells for regulated insulin secretion using rAAV-mediated gene transfer |
| Q47920466 | Dietary Slowly Digestible Starch Triggers the Gut-Brain Axis in Obese Rats with Accompanied Reduced Food Intake |
| Q38073233 | Digestive physiology of the pig symposium: secretion of gastrointestinal hormones and eating control |
| Q34289440 | Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. |
| Q54156279 | Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. |
| Q52865882 | Effect of large bowel fermentation on insulin, glucose, free fatty acids, and glucagon-like peptide 1 (7-36) amide in patients with coronary heart disease. |
| Q35584652 | Effect of macronutrient composition on short-term food intake and weight loss |
| Q27011627 | Effects of GLP-1 on appetite and weight |
| Q44396038 | Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans |
| Q34810392 | Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model |
| Q46349264 | Effects of oral fat perception by modified sham feeding on energy expenditure, hormones and appetite profile in the postprandial state |
| Q51561423 | Effects of oral fructose and glucose on plasma GLP-1 and appetite in normal subjects. |
| Q42059121 | Electrical activity-triggered glucagon-like peptide-1 secretion from primary murine L-cells |
| Q34620465 | Emerging role of GLP-1 receptor agonists in the treatment of obesity |
| Q45061310 | Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection |
| Q35545683 | Enhancing Incretin Action for the Treatment of Type 2 Diabetes |
| Q46644422 | Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation. |
| Q45253690 | Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. |
| Q34120699 | Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes |
| Q37913052 | Exocrine pancreatic insufficiency in diabetes mellitus: a complication of diabetic neuropathy or a different type of diabetes? |
| Q46584956 | Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid |
| Q45066824 | GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. |
| Q58449053 | GLP-1 does not acutely affect insulin sensitivity in healthy man |
| Q34727731 | GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. |
| Q100945923 | GLP-1 receptor agonist ameliorates experimental lung fibrosis |
| Q45242151 | GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats |
| Q58763580 | GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca channels |
| Q43105364 | GLP-1(28-36)amide, a Long Ignored Peptide Revisited |
| Q43664555 | GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve |
| Q90016044 | GLP-1: Molecular mechanisms and outcomes of a complex signaling system |
| Q39759027 | Gastric emptying and release of incretin hormones after glucose ingestion in humans |
| Q39047697 | Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. |
| Q38628696 | Glucagon-Like Peptide-1 Formulation--the Present and Future Development in Diabetes Treatment |
| Q89442824 | Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function |
| Q36309183 | Glucagon-like peptide 1 (GLP-1) and metabolic diseases |
| Q37501257 | Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity |
| Q34401791 | Glucagon-like peptide 1(GLP-1) in biology and pathology |
| Q51565507 | Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. |
| Q46278128 | Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication |
| Q37598515 | Glucagon-like peptide-1 secreting cell function as well as production of inflammatory reactive oxygen species is differently regulated by glycated serum and high levels of glucose |
| Q35565562 | Glucagon-like peptide-1: a potent regulator of food intake in humans |
| Q48045877 | Glucose concentrations modulate brain-derived neurotrophic factor responsiveness of neurones in the paraventricular nucleus of the hypothalamus. |
| Q34890796 | Glucose sensing in L cells: a primary cell study |
| Q48866872 | Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. |
| Q47280771 | Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells |
| Q41830120 | Glucose-dependent insulinotropic polypeptide regulates dipeptide absorption in mouse jejunum |
| Q37911549 | Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders |
| Q58448029 | Glutamine Reduces Postprandial Glycemia and Augments the Glucagon-Like Peptide-1 Response in Type 2 Diabetes Patients |
| Q40516007 | Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. |
| Q42946022 | Glycemic Index and Glucose Utilization of Rice Vermicelli in Healthy Subjects |
| Q37057996 | Gut hormones as potential new targets for appetite regulation and the treatment of obesity |
| Q36614364 | Gut peptide signaling in the controls of food intake |
| Q35688209 | Gut peptides in the treatment of diabetes mellitus |
| Q28081671 | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide |
| Q48616153 | High-fat diet effects on gut motility, hormone, and appetite responses to duodenal lipid in healthy men. |
| Q37420818 | Hormonal regulators of appetite |
| Q34890607 | Hungry for life: How the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction |
| Q46477363 | Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides |
| Q48682731 | Identification of amidated forms of GLP-1 in rat tissues using a highly sensitive radioimmunoassay |
| Q93083828 | Ileal transposition rapidly improves glucose tolerance and gradually improves insulin resistance in non-obese type 2 diabetic rats |
| Q77909734 | Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose |
| Q34519292 | Impaired enteroendocrine development in intestinal-specific Islet1 mouse mutants causes impaired glucose homeostasis |
| Q38911347 | In vitro bioactive properties of intact and enzymatically hydrolysed whey protein: targeting the enteroinsular axis |
| Q26744254 | Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? |
| Q46494673 | Incretin and islet hormonal responses to fat and protein ingestion in healthy men. |
| Q73119582 | Incretin hormone expression in the gut of diabetic mice and rats |
| Q35962037 | Incretin mimetics as emerging treatments for type 2 diabetes |
| Q37082698 | Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering |
| Q27301386 | Indirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in mice |
| Q57110457 | Influences of protein ingestion on glucagon-like peptide (GLP)-1-immunoreactive endocrine cells in the chicken ileum |
| Q36731945 | Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. |
| Q38105423 | Integration of satiety signals by the central nervous system |
| Q41286188 | Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells |
| Q38575560 | Intestinal GLP-1 and satiation: from man to rodents and back |
| Q43166019 | Intestinal hormones and growth factors: effects on the small intestine |
| Q88039779 | Intragastric nutrient infusion reduces motivation for food in male and female rats |
| Q47295180 | Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. |
| Q92177903 | L-phenylalanine Increased Gut Hormone Secretion through Calcium-Sensing Receptor in the Porcine Duodenum |
| Q37218440 | Lack of Effects of a Single High-Fat Meal Enriched with Vegetable n-3 or a Combination of Vegetable and Marine n-3 Fatty Acids on Intestinal Peptide Release and Adipokines in Healthy Female Subjects |
| Q42037657 | Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression |
| Q43541711 | Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans |
| Q40215541 | Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases |
| Q54879432 | Mechanisms responsible for homeostatic appetite control: theoretical advances and practical implications |
| Q37050373 | Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery |
| Q37667168 | Molecular mechanisms underlying nutrient-stimulated incretin secretion |
| Q37635255 | Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. |
| Q35612377 | Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion |
| Q40029149 | Novel insight into the distribution of L-cells in the rat intestinal tract |
| Q38100206 | Novel therapeutic targets for nonalcoholic fatty liver disease |
| Q100428031 | Nutrient consumption-dependent association of a glucagon-like peptide-1 receptor gene polymorphism with insulin secretion |
| Q28564632 | Nutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar rats |
| Q50017971 | Nutritional Health Considerations for Persons with Spinal Cord Injury |
| Q37322912 | Nutritional regulation of glucagon-like peptide-1 secretion |
| Q33607971 | Obesity treatment: novel peripheral targets |
| Q34310033 | Oral and gastrointestinal sensing of dietary fat and appetite regulation in humans: modification by diet and obesity |
| Q35121793 | Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects |
| Q26766485 | Pancreatic regulation of glucose homeostasis |
| Q64095007 | Peptone-mediated glucagon-like peptide-1 secretion depends on intestinal absorption and activation of basolaterally located Calcium-Sensing Receptors |
| Q36753785 | Peripheral tissue-brain interactions in the regulation of food intake |
| Q35760279 | Physiology of incretins in health and disease |
| Q44105567 | Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. |
| Q37514681 | Postprandial metabolite profiles reveal differential nutrient handling after bariatric surgery compared with matched caloric restriction |
| Q37940632 | Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants |
| Q39341291 | Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. |
| Q36759089 | Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology |
| Q34452524 | Proglucagon-derived peptides: mechanisms of action and therapeutic potential |
| Q33593471 | Protein Digestion-Derived Peptides and the Peripheral Regulation of Food Intake |
| Q38077226 | Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. |
| Q37857695 | Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes |
| Q37086245 | Reducing dietary fat from a meal increases the bioavailability of exogenous carbohydrate without altering plasma glucose concentration |
| Q47698901 | Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. |
| Q27316004 | Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice |
| Q38057350 | Review article: a comparison of glucagon-like peptides 1 and 2. |
| Q36503839 | Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease |
| Q36208149 | Role of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes |
| Q37185214 | Role of central glucagon-like peptide-1 in stress regulation |
| Q35766237 | Role of gastrointestinal hormones in feeding behavior and obesity treatment |
| Q45251300 | Role of nitric oxide mechanisms in gastric emptying of, and the blood pressure and glycemic responses to, oral glucose in healthy older subjects |
| Q58449063 | Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day |
| Q77921891 | Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans |
| Q34012977 | Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth |
| Q47144515 | Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes? |
| Q42488494 | Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum |
| Q64086648 | Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives |
| Q37337560 | Sweetness and bitterness taste of meals per se does not mediate gastric emptying in humans. |
| Q35895745 | TRPM5 is critical for linoleic acid-induced CCK secretion from the enteroendocrine cell line, STC-1 |
| Q39220481 | The G protein-coupled receptor family C group 6 subtype A (GPRC6A) receptor is involved in amino acid-induced glucagon-like peptide-1 secretion from GLUTag cells |
| Q58448995 | The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide |
| Q31131497 | The TRPA1 agonist, methyl syringate suppresses food intake and gastric emptying |
| Q51456278 | The alpha (α)-glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow responses to intraduodenal sucrose in older adults. |
| Q50865058 | The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. |
| Q35543158 | The effect on glucagon, glucagon-like peptide-1, total and acyl-ghrelin of dietary fats ingested with and without potato |
| Q44240035 | The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno--ileal loop? |
| Q38036910 | The effects of food components on hormonal signalling in gastrointestinal enteroendocrine cells. |
| Q30357431 | The future role of gut hormones in the treatment of obesity |
| Q38036016 | The gut endocrine system as a coordinator of postprandial nutrient homoeostasis |
| Q36187070 | The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q48126453 | The individual and combined effects of glycemic index and protein on glycemic response, hunger, and energy intake |
| Q40362301 | The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line. |
| Q35358986 | The postprandial rise in plasma cortisol in men is mediated by macronutrient-specific stimulation of adrenal and extra-adrenal cortisol production |
| Q38019805 | The regulation of food intake by the gut-brain axis: implications for obesity |
| Q33953674 | The relevance of the glycaemic index to our understanding of dietary carbohydrates |
| Q38101677 | The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q99564753 | The triterpenoid sapogenin (2α-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling |
| Q34778864 | The vagus nerve, food intake and obesity |
| Q36093376 | Uncoupling protein 2 regulates glucagon-like peptide-1 secretion in L-cells |
| Q42526184 | Using the lymph fistula rat model to study the potentiation of GIP secretion by the ingestion of fat and glucose |
| Q38271009 | Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats |
| Q74316848 | [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1] |
| Q83079212 | [Early improvement in Type 2 diabetes in obese patients following gastric bypass and bilio-pancreatic diversion: the role of the entero-insular axis] |
Search more.